Welcome to the March edition of our newsletter! Bringing you our latest discoveries in high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. Visit us at: moleculardevices.com
Blog: Timeline of COVID-19 solutions to the challenges of diagnosis, treatment, and mitigation
Explore the landmark biotechnology breakthroughs from COVID-19 research of 2020 and 2021 in our latest infographic blog. The SARS-CoV-2 virus, the causative agent for COVID-19 and the worst pandemic in modern history, was first identified in isolated cases in late 2019.
Learn more about:
The commercialization of the first COVID PCR test
The race to develop and scale therapeutic antibodies
Cell line development hurdles in the production of a COVID-19 vaccine
Get consistent, unbiased, and biologically relevant results at scale
Watch how our new Organoid Innovation Center combines cutting-edge technologies with novel 3D biology methods to address key challenges when scaling complex 3D biology. An end-to-end solution standardizes the organoid development process with cell culture, treatment, and incubation, through to imaging, analysis, and data processing to deliver more in-depth results at scale.
Lab automation for high-throughput plate-based assays
Explore our fully-integrated, automated workflow solutions for cell and biochemical assays
As timelines compress and the amount of data required for IND submissions and publications increase, laboratories are pressed to do more with less. We can build flexible, scalable, future-proof workflows backed by decades of consultative expertise to help you design and implement workcells that incorporate industry-leading technology to achieve your goals.
Blog: Importance of regulatory compliance in GMP and GLP labs
The regulations for food and drug in the United States, described in Title 21 of the Code of Federal Regulations, are critical in ensuring safe and ethical drug administration. Whether you are an academic institution, a government agency, or a pharmaceutical company, you must adhere to these rules at each step of the drug development process. Failure to do so could even cascade into a corporate shutdown in the long run.
Read about the essential components of regulatory compliance in GxP labs and our approach to achieving and maintaining these standards.
Podcast: Why mAbs are key in the fight against SARS-CoV-2
We are proud to announce our exclusive podcast sponsorship with Drug Target Review.
In this episode, editor Victoria Rees speaks with Dr. Carter Mitchell, Chief Science Officer, and Dr. Sharath Madasu, Manager of Protein Characterization at Kemp Proteins about the use of monoclonal antibodies (mAbs) against SARS-CoV-2, and the ways the development workflows have evolved over the course of the pandemic.
Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.